HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
vvSkh8WR22Zeu3Xn